This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
Read original at benzingaStocks · News reference
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78
Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $80 to $78.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 12:33 PM
- Checked
- Aug 12, 2026, 12:33 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $48 to $49.
Read original at benzingaTD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24
TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and lowers the price target from $29 to $24.
Read original at benzingaOppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40
Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.
Read original at benzinga